Sokal Risk Score Is Superior to Hasford and EUTOS in Determining Survival Outcomes for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients

被引：0
|
作者：
Jiang, Brian Gabriel [1 ]
Kim, Dong-Wook [2 ]
Shih, Lee-Yung [3 ]
Chuah, Charles [4 ,5 ]
Than, Hein [4 ]
Kuo, Ming-Chung [6 ,7 ]
Li, HuiHua [8 ]
Allen, John Carson, Jr. [9 ]
See, Lionel K. Y. [10 ]
Yap, Bernard K. C. [10 ]
Goh, Yeow-Tee [4 ,10 ]
机构：
[1] Duke Univ, Sch Med, Durham, NC USA
[2] St Marys Hosp, Dept Haematol, Seoul, South Korea
[3] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp Linkou, Dept Hematol Oncol, Taipei, Taiwan
[4] Singapore Gen Hosp, Dept Hematol, Singapore, Singapore
[5] Duke NUS Grad Med Sch, Canc & Stem Cell Biol Signature Res Program, Singapore, Singapore
[6] Chang Gung Mem Hosp Linkou, Taoyuan, Taiwan
[7] Chang Gung Univ, Taoyuan, Taiwan
[8] Hlth Serv Res, Singapore, Singapore
[9] Duke NUS Grad Med Sch, Ctr Quantitat Med, Singapore, Singapore
[10] Duke NUS Grad Med Sch, Singapore, Singapore
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase
    Michihide Tokuhira
    Yuta Kimura
    Keiji Sugimoto
    Tomonori Nakazato
    Maho Ishikawa
    Isao Fujioka
    Tomoiku Takaku
    Noriyoshi Iriyama
    Eriko Sato
    Hiroyuki Fujita
    Yoshihiro Hatta
    Norio Komatsu
    Norio Asou
    Masahiro Kizaki
    Tatsuya Kawaguchi
    Medical Oncology, 2018, 35
  • [32] Imatinib mesylate in newly diagnosed patients of chronic myeloid leukemia chronic phase: A comparative study
    Jacob, L. A.
    Bapsy, P. P.
    Govindbabu, K.
    Lokanatha, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase
    Fallah, P.
    Amirizadeh, N.
    Poopak, B.
    Toogeh, G.
    Arefian, E.
    Kohram, F.
    Rad, S. M. A. Hosseini
    Kohram, M.
    Naghadeh, H. Teimori
    Soleimani, M.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2015, 37 (04) : 560 - 568
  • [34] Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase
    Tokuhira, Michihide
    Kimura, Yuta
    Sugimoto, Keiji
    Nakazato, Tomonori
    Ishikawa, Maho
    Fujioka, Isao
    Takaku, Tomoiku
    Iriyama, Noriyoshi
    Sato, Eriko
    Fujita, Hiroyuki
    Hatta, Yoshihiro
    Komatsu, Norio
    Asou, Norio
    Kizaki, Masahiro
    Kawaguchi, Tatsuya
    MEDICAL ONCOLOGY, 2018, 35 (03)
  • [35] The pros and cons of new prognostic eutos score for chronic myeloid leukemia patients
    Breccia, Massimo
    Alimena, Giuliana
    LEUKEMIA RESEARCH, 2013, 37 (11) : 1436 - 1437
  • [36] Impact of risk score calculations in choosing front-line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase
    Hu, Bei
    Savani, Bipin N.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 93 (03) : 179 - 186
  • [37] EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience
    Jabbour, Elias
    Cortes, Jorge
    Nazha, Aziz
    O'Brien, Susan
    Quintas-Cardama, Alfonso
    Pierce, Sherry
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    BLOOD, 2012, 119 (19) : 4524 - 4526
  • [38] Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia
    Ishida, Yoji
    Murai, Kazunori
    Yamaguchi, Kohei
    Miyagishima, Takuto
    Shindo, Motohiro
    Ogawa, Kazuei
    Nagashima, Takahiro
    Sato, Shinji
    Watanabe, Reiko
    Yamamoto, Satoshi
    Hirose, Takayuki
    Saitou, Souich
    Yonezumi, Masakatsu
    Kondo, Takeshi
    Kato, Yuichi
    Mochizuki, Noboru
    Ohno, Keiko
    Kishino, Satoshi
    Kubo, Kohmei
    Oyake, Tatsuo
    Ito, Shigeki
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (02) : 185 - 193
  • [39] Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia
    Yoji Ishida
    Kazunori Murai
    Kohei Yamaguchi
    Takuto Miyagishima
    Motohiro Shindo
    Kazuei Ogawa
    Takahiro Nagashima
    Shinji Sato
    Reiko Watanabe
    Satoshi Yamamoto
    Takayuki Hirose
    Souich Saitou
    Masakatsu Yonezumi
    Takeshi Kondo
    Yuichi Kato
    Noboru Mochizuki
    Keiko Ohno
    Satoshi Kishino
    Kohmei Kubo
    Tatsuo Oyake
    Shigeki Ito
    European Journal of Clinical Pharmacology, 2016, 72 : 185 - 193
  • [40] Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
    Chen, Suning
    Zhang, Yanli
    Xu, Na
    Sun, Hui
    Li Weiming
    Yang, Yunfan
    Zhu, Zunmin
    Duan, Minghui
    Qian, Sixuan
    Zhu, Yu
    Luo, Jianmin
    Wang, Xiaodong
    Yang, Wei
    Gu, Weiying
    Li, Fei
    Liu, Bingcheng
    Xu, Yunxiao
    Liu, Zhenfang
    Wang, Chunling
    Jiang, Yirong
    Meng, Li
    Wen, Qin
    Xu, Yanli
    Zou, Xingli
    Wang, Wei
    Xue, Yan
    Xu, Hao
    Bi, Kehong
    Zhou, Fuling
    Ma, Liangming
    Fu, Rong
    Ouyang, Guifang
    Ding, Kaiyang
    Wu, Depei
    BLOOD, 2023, 142
12345